Kesavadev J, et al. - The impact of sitagliptin (100 mg) versus glimepiride (1-3 mg) as add-on therapy in Indian type 2 diabetes (T2DM) patients on treatment with insulin and metformin (SWIM study) is compared in this study. Sitagliptin (100 mg) when compared to glimepiride (1-3 mg), bestowed beneficial impacts to T2DM patients in terms of achieving greater glycaemic control and also brought significant reductions in total daily dose of insulin required, body weight, BMI and hypoglycemic events. In general, the outcomes propose that sitagliptin (100 mg) is a better agent over glimepiride (1-3 mg) as an add-on to insulin-metformin therapy among Asian Indians with T2DM.